PATENT CLAIM ANALYSIS

Application Number: 15977572
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "001300"]

Abstract:
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Claim (Index 30):
A conjugate having a formula B-L-D\n or a pharmaceutically acceptable salt thereof; wherein\n B is a radical of a PSMA binding ligand having the formula \n wherein * is the point of attachment to L;\n L is a polyvalent linker comprising a portion having the formula \n wherein at least one AA is an amino acid in an unnatural configuration; n is 3 or greater; m1, m2, m3, q, r, and p are each 0, and each ** is a point of attachment to the rest of the conjugate; and\n D is a therapeutic agent or a radioactive isotope of a metal coordinated to a chelating group.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.72727
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14443212', '15245505', '15606913', '12530952', '15959110']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7217243697463857
- 35 USC 102 Novelty (BERT): 0.5419715041023425
- Combined Prediction Score: 0.7037490831819813
- Mean Citation Score: 320.46455
- Max Citation Score: 390.5377
- Similarity Product: 294.9148779036581

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test